fbpx

Belviq Weight Loss Drugs Withdrawn Without Compensation Complaint

November 11, 2021

On its first presentation to the Food and Drug Administration (FDA) for approval, the weight-loss drug Belviq was rejected. After some additional studies, it was accepted by the FDA in 2012. This class action brings suit against Eisai, Inc. and Arena Pharmaceuticals over Belviq and Belviq XR, alleging that the companies knew the drugs increase the consumers’ risk of cancer, and that the companies did not give any compensation to those who had bought the drugs and had to stop taking them when they were withdrawn from the market.

Case Event File: Belviq Weight Loss Drugs Withdrawn Without Compensation Complaint

Related to: Belviq Weight Loss Drugs Withdrawn Without Compensation Class Action